Last reviewed · How we verify

NCT05553418

Investigational On-body Injector Clinical Study

Completed NA Last updated 3 February 2025
What this trial tests

NA trial testing In-clinic wear first in Healthy Volunteers in 70 participants. Completed in 8 February 2023.

Timeline
5 September 2022
Primary endpoint
8 February 2023
8 February 2023

Quick facts

Lead sponsorBecton, Dickinson and Company
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment70
Start date5 September 2022
Primary completion8 February 2023
Estimated completion8 February 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Becton, Dickinson and Company — full company profile →

Who can join

18 and older, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the clinical feasibility, performance, safety and acceptability of the On-body Injector (OBI) when applied to the arm or abdomen of healthy volunteers to inject placebo under the skin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other Becton, Dickinson and Company trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05553418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing